InvestorsHub Logo
Followers 52
Posts 3332
Boards Moderated 0
Alias Born 10/26/2013

Re: None

Monday, 12/18/2017 8:51:30 AM

Monday, December 18, 2017 8:51:30 AM

Post# of 3283

Spectrum Pharmaceuticals initiated with Buy rating and $26 (37% upside) price target by B. Riley FBR citing expected revenue of $125M - 130M through 2019 from oncology products and upside from Rolontis and poziotinib starting in 2020. Shares are up 3% premarket on light volume.

A blip from Seeking Alpha. Appears to be that a new investment house is interested in SPPI.